Knight Therapeutics logo Knight Therapeutics Inc (TSE:GUD) – Stock analysts at Cormark lifted their Q1 2019 earnings estimates for shares of Knight Therapeutics in a research note issued to investors on Thursday, February 21st, Zacks Investment Research reports. Cormark analyst T. Gonsalves now anticipates that the company will post earnings of $0.03 per share for the quarter, up from their previous estimate of $0.02. Cormark also issued estimates for Knight Therapeutics’ FY2019 earnings at $0.12 EPS.
Knight Therapeutics (TSE:GUD) last released its quarterly earnings results on Thursday, March 14th. The company reported C$0.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of C$0.03 by C$0.01. The company had revenue of C$3.89 million during the quarter, compared to analyst estimates of C$2.55 million.
Separately, Raymond James set a C$10.25 price target on Knight Therapeutics and gave the company an “outperform” rating in a report on Friday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of C$10.06.
TSE GUD traded up C$0.46 during trading on Friday, reaching C$8.01. 3,544,100 shares of the company’s stock were exchanged, compared to its average volume of 346,156. Knight Therapeutics has a fifty-two week low of C$7.35 and a fifty-two week high of C$8.81. The firm has a market capitalization of $1.14 billion and a PE ratio of 36.91.
Knight Therapeutics Company Profile
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Featured Story: How To Calculate Debt-to-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Knight Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Knight Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Knight Therapeutics Inc (GUD) Forecasted to Post Q1 2019 Earnings of $0.03 Per Share